E
Edgewise Therapeutics
A new biotech company harnessing proven expertise and understanding of skeletal muscle
About Edgewise Therapeutics
Edgewise Therapeutics is a biotechnology company focused on developing innovative therapies for rare muscle disorders such as Duchenne, Becker, and Limb Girdle muscular dystrophies, as well as McArdle disease. Utilizing a proprietary drug discovery platform, the company aims to create a holistic therapeutic approach to protect muscle health. Edgewise Therapeutics serves patients and families affected by these progressive muscle disorders, operating within the niche market of precision medicine for rare diseases. The business model involves retaining global development and commercialization rights to its programs, allowing for strategic collaborations and asset acquisitions to accelerate development and expand its pipeline. Revenue is generated through the development and commercialization of its lead molecule, sevasemten (EDG 5506), which targets the muscle motor protein myosin to reduce stress in fast skeletal muscle fibers without affecting other muscle types.
Source: Dealroom company dataAt a glance
- Founded
- 2017
- Headquarters
- Boulder, United States
- Listing
- IPO 2021
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
U.S. Venture Partners
Novo Seeds
Novo Ventures
Series B and later17 investors entered at this stage
Viking Global Investors
New Leaf Venture Partners
OrbiMed
Janus Henderson Investors
Wellington Management
Citadel
Logos Capital
Novo Holdings
Deerfield
Cormorant Asset Management
RA Capital Management
Cure Duchenne
Surveyor Capital
TCGX
Frazier Life Sciences
Perceptive Advisors- VPVenrock Healthcare Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
14 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Edgewise Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Edgewise Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.